Breaking News Instant updates and real-time market news.

NLNK

NewLink Genetics

$9.00

-1.06 (-10.54%)

, INCY

Incyte

$99.85

1.41 (1.43%)

13:42
01/08/18
01/08
13:42
01/08/18
13:42

NewLink Genetics timelines mostly in-line with prior guidance, says Stifel

Stifel analyst Stephen Willey noted that NewLink Genetics (NLNK) now expects to complete the majority of enrollment in the Indigo301 melanoma trial by year-end, versus its previous expectation to complete enrollment in 2018, which he said is likely due to additional time required for dose optimization of the novel indoximod salt formulation. The remainder of the 2018 calendar the company laid out is full of mostly expected catalysts and in-line with prior guidance, said Willey, who still expects NewLink to remain levered to Incyte's (INCY) date from the Phase 3 ECHO-301 trial. Willey keeps a Buy rating on NewLink shares.

NLNK

NewLink Genetics

$9.00

-1.06 (-10.54%)

INCY

Incyte

$99.85

1.41 (1.43%)

  • 18

    Jan

  • 25

    Jan

NLNK NewLink Genetics
$9.00

-1.06 (-10.54%)

10/13/17
BOFA
10/13/17
INITIATION
Target $22
BOFA
Buy
NewLink Genetics initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Ying Huang initiated NewLing Genetics with a Buy and $22 price target saying shares are undervalued. The analyst said Newlink is focused on development of indoximod, an IDO pathway inhibitor, which could become a "backbone" therapy for cancer treatment.
10/13/17
10/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Visa (V) and MasterCard (MA) were initiated with an Overweight at Stephens. 2. Acuity Brands (AYI) initiated with a Sector Weight at KeyBanc. 3. Williams-Sonoma (WSM) and RH (RH) were initiated with a Hold at Stifel. 4. Signature Bank (SBNY) assumed with a Neutral at Piper Jaffray. 5. NewLink Genetics (NLNK) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/03/17
STFL
11/03/17
NO CHANGE
Target $25
STFL
Buy
NewLink Genetics price target lowered to $25 from $29 at Stifel
Stifel analyst Stephen Willey trimmed his price target on NewLink Genetics (NLNK) to $25 from $29 to reflect incremental dilution from its recent equity fundraising and forecast for increased operating expenses given that the company will soon initiate its pivotal Phase 3 melanoma trial. The analyst, who expects NewLink shares to remain sensitive to near-term data points on the IDO inhibitor front from Bristol-Myers (BMY) and the partnership of Incyte (INCY) and Merck (MRK), keeps a Buy rating on NewLink shares.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
INCY Incyte
$99.85

1.41 (1.43%)

01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
Incyte upgraded to Outperform at RBC Capital on improved risk-reward
As reported earlier, RBC Capital analyst Brian Abrahams upgraded Incyte to Outperform from Sector Perform. Abrahams says the 31% decline in the stock price from the September high makes for more substantially improved risk-reward profile as expectations for the phase 3 epa melanoma readout have come down. The analyst says he remains bullish on the long-term growth prospects for Jakafi, modeling its undiscounted, taxed cash flows through end-2026 patent expiry of about $14B.
01/02/18
OPCO
01/02/18
NO CHANGE
Target $120
OPCO
Perform
Incyte price target lowered to $120 from $135 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte to $120 from $135, citing share underperformed following the presentation of updated ECHO-202 data for epacadostat+Keytruda in advanced melanoma at ESMO. The analyst believes the Incyte share price decline was driven by loss of M&A premium as investors became disappointed by limited Biotech deal activity, concern about potential share price impact of ECHO-301 results in 1H18, and nervousness about the data at ESMO. Olson reiterates an Perform rating on the shares.
01/08/18
DBAB
01/08/18
NO CHANGE
Target $110
DBAB
Buy
Celgene deal 'incremental negative' for Incyte, says Deutsche Bank
Deutsche Bank analyst Navin Jacob calls Celgene's (CELG) acquisition of Impact Biomedicines "one step" in the right direction. The analyst estimates Impact's Jak2 inhibitor fedratinib can achieve 20% of peak Jakafi sales in myelofibrosis and polycythemia vera, which translates to $1B. The asset fits Celgene's business and the $2.4B that the company is paying over the next two years "doesn't appear egregious for a commercial ready asset," Jacob tells investors in a research note. The analyst also views Celgene's acquisition as an "incremental negative" for Incyte (INCY). Given direct overlap, any future potential acquisition of Incyte by Celgene has been removed, Jacob contends. He keeps a Hold rating on Celgene with a $110 price target.

TODAY'S FREE FLY STORIES

GPRO

GoPro

$6.30

0.01 (0.16%)

, JPM

JPMorgan

$114.46

0.13 (0.11%)

12:35
01/23/18
01/23
12:35
01/23/18
12:35
Hot Stocks
GoPro falls after Morgan Stanley downgrade cites limited strategic value »

Shares of GoPro (GPRO)…

GPRO

GoPro

$6.30

0.01 (0.16%)

JPM

JPMorgan

$114.46

0.13 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 07

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MET

MetLife

$53.56

-0.29 (-0.54%)

12:31
01/23/18
01/23
12:31
01/23/18
12:31
Hot Stocks
MetLife issues statement on court decision to dismiss appeal in SIFI litigation »

MetLife chairman,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 12

    Jun

CVE

Cenovus Energy

$10.43

0.04 (0.38%)

12:30
01/23/18
01/23
12:30
01/23/18
12:30
Options
Call buyers in Cenovus Energy as shares tick higher »

Call buyers in Cenovus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$135.52

0.31 (0.23%)

12:28
01/23/18
01/23
12:28
01/23/18
12:28
Technical Analysis
Technical Earnings Preview: United Technologies in uptrend before news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AGN

Allergan

$187.32

-0.83 (-0.44%)

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Options
Allergan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Conference/Events
Leerink healthcare services analysts hold an analyst/industry conference call »

Healthcare Services…

VZ

Verizon

$53.23

-0.235 (-0.44%)

12:22
01/23/18
01/23
12:22
01/23/18
12:22
Periodicals
Verizon giving employees 50 shares of restricted stock, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

CHFN

Charter Financial

$18.13

-0.12 (-0.66%)

12:21
01/23/18
01/23
12:21
01/23/18
12:21
Hot Stocks
Charter Financial raises quarterly dividend to 8c per share from 5c »

Charter Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$36.96

0.7 (1.93%)

, FOXA

21st Century Fox

$37.31

0.66 (1.80%)

12:20
01/23/18
01/23
12:20
01/23/18
12:20
Hot Stocks
21st Century Fox 'welcomes' part of CMA finding, 'disappointed' about plurality »

21st Century Fox (FOXA)…

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

SKYAY

Sky

$55.97

0.72 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 07

    Feb

$NSD

NASDAQ Market Internals

12:17
01/23/18
01/23
12:17
01/23/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Hot Stocks
Netflix's 'Mudbound' gets four Oscar noms, Amazon's 'The Big Sick' gets nod »

Films produced by Netflix…

NFLX

Netflix

$227.58

7.12 (3.23%)

AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 01

    Feb

  • 18

    Mar

$NYE

NYSE Market Internals

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$16.46

0.41 (2.55%)

12:15
01/23/18
01/23
12:15
01/23/18
12:15
Options
Hewlett Packard Enterprise put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

, TRV

Travelers

$145.27

5.92 (4.25%)

12:10
01/23/18
01/23
12:10
01/23/18
12:10
General news
On The Fly: Top stock stories at midday »

Stocks opened little…

NFLX

Netflix

$227.58

7.12 (3.23%)

TRV

Travelers

$145.27

5.92 (4.25%)

VZ

Verizon

$53.31

-0.15 (-0.28%)

JNJ

Johnson & Johnson

$143.58

-4.565 (-3.08%)

PG

Procter & Gamble

$89.11

-2.78 (-3.03%)

TSLA

Tesla

$351.56

1.54 (0.44%)

RMD

ResMed

$103.82

16.306 (18.63%)

WHR

Whirlpool

$171.12

4.47 (2.68%)

TWTR

Twitter

$22.96

-0.36 (-1.54%)

INSM

Insmed

$30.86

1.58 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 30

    Jan

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

UAL

United Continental

$76.96

0.09 (0.12%)

12:07
01/23/18
01/23
12:07
01/23/18
12:07
Technical Analysis
Technical Earnings Preview: United Continental has a potential bullish pattern »

Heading into earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

RHHBY

Roche

$30.79

0.1 (0.33%)

12:05
01/23/18
01/23
12:05
01/23/18
12:05
Hot Stocks
Roche subsidiary treatment of gastric cancer granted FDA orphan status »

Genentech, a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 23

    Feb

SQ

Square

$44.69

-0.6 (-1.32%)

12:05
01/23/18
01/23
12:05
01/23/18
12:05
Options
Square call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

ATVI

Activision Blizzard

$71.30

0.73 (1.03%)

12:04
01/23/18
01/23
12:04
01/23/18
12:04
Recommendations
Activision Blizzard analyst commentary  »

Cowen sees 'some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

MDCO

The Medicines Co.

$28.81

3.98 (16.03%)

12:04
01/23/18
01/23
12:04
01/23/18
12:04
Hot Stocks
The Medicines Co. treatment of HoFH granted FDA orphan designation »

The FDA granted orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TRNC

tronc

$21.00

1.47 (7.53%)

12:01
01/23/18
01/23
12:01
01/23/18
12:01
Periodicals
Tronc in talks for news partnership with Axios, WSJ says »

Los Angeles Times owner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CREE

Cree

$36.69

0.4 (1.10%)

11:59
01/23/18
01/23
11:59
01/23/18
11:59
Technical Analysis
Technical Earnings Preview: Cree has a potential bearish pattern »

Ahead of earnings news,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ARNA

Arena Pharmaceuticals

$35.89

0.29 (0.81%)

11:58
01/23/18
01/23
11:58
01/23/18
11:58
Conference/Events
Arena Pharmaceuticals to hold Key Opinion Leader Event »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$235.01

-9.12 (-3.74%)

11:57
01/23/18
01/23
11:57
01/23/18
11:57
Recommendations
Ulta Beauty analyst commentary  »

Ulta Beauty coupon likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCG

Scana

$43.80

0.44 (1.01%)

11:55
01/23/18
01/23
11:55
01/23/18
11:55
Options
SCANA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
01/23/18
01/23
11:55
01/23/18
11:55
General news
Fed board nominee Goodfriend said the Fed was on the right path »

Fed board nominee…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.